radioactive iodine refractory differentiated thyroid cancer
Oncology · 2015–2016
2decisions
1medicine
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lenvatinib Treatment of radioactive iodine refractory differentiated thyroid cancer (RAI-R DTC) that is locally advanced or metastatic. | Jul 2016 | Recommended | no section in document |
| lenvatinib Treatment of radioactive iodine refractory differentiated thyroid cancer stage III or IV in patients with symptomatic progressive disease. | Nov 2015 | Deferred | none received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.